These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 38670473)

  • 1. Is it advantageous to use quality by design (QbD) to develop nanoparticle-based dosage forms for parenteral drug administration?
    Camacho Vieira C; Peltonen L; Karttunen AP; Ribeiro AJ
    Int J Pharm; 2024 May; 657():124163. PubMed ID: 38670473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Product Development, Manufacturing, and Packaging of Solid Dosage Forms Under QbD and PAT Paradigm: DOE Case Studies for Industrial Applications.
    Singh BN
    AAPS PharmSciTech; 2019 Sep; 20(8):313. PubMed ID: 31529232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quality by design and process analytical technology for sterile products--where are we now?
    Riley BS; Li X
    AAPS PharmSciTech; 2011 Mar; 12(1):114-8. PubMed ID: 21181513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toward Higher QA: From Parametric Release of Sterile Parenteral Products to PAT for Other Pharmaceutical Dosage Forms.
    Hock SC; Constance NX; Wah CL
    PDA J Pharm Sci Technol; 2012; 66(4):371-91. PubMed ID: 22767885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Quality by Design Approach to Developing and Manufacturing Polymeric Nanoparticle Drug Products.
    Troiano G; Nolan J; Parsons D; Van Geen Hoven C; Zale S
    AAPS J; 2016 Nov; 18(6):1354-1365. PubMed ID: 27631558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmaceutical product development: A quality by design approach.
    Pramod K; Tahir MA; Charoo NA; Ansari SH; Ali J
    Int J Pharm Investig; 2016; 6(3):129-38. PubMed ID: 27606256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Administration of drug and nutritional components in nano-engineered form to increase delivery ratio and reduce current inefficient practice.
    Valtcheva-Sarker RV; O'Reilly JD; Sarker DK
    Recent Pat Drug Deliv Formul; 2007; 1(2):147-59. PubMed ID: 19075882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Excipient variability and its impact on dosage form functionality.
    Dave VS; Saoji SD; Raut NA; Haware RV
    J Pharm Sci; 2015 Mar; 104(3):906-15. PubMed ID: 25561249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quality by design (QbD) approaches in current pharmaceutical set-up.
    Mishra V; Thakur S; Patil A; Shukla A
    Expert Opin Drug Deliv; 2018 Aug; 15(8):737-758. PubMed ID: 30044646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quality by design (QbD) approach in marketing authorization procedures of Non-Biological Complex Drugs: A critical evaluation.
    Zagalo DM; Sousa J; Simões S
    Eur J Pharm Biopharm; 2022 Sep; 178():1-24. PubMed ID: 35908664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmaceutical quality by design: product and process development, understanding, and control.
    Yu LX
    Pharm Res; 2008 Apr; 25(4):781-91. PubMed ID: 18185986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. QbD guided early pharmaceutical development study: Production of lipid nanoparticles by high pressure homogenization for skin cancer treatment.
    Amasya G; Aksu B; Badilli U; Onay-Besikci A; Tarimci N
    Int J Pharm; 2019 May; 563():110-121. PubMed ID: 30935913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nanosizing for oral and parenteral drug delivery: a perspective on formulating poorly-water soluble compounds using wet media milling technology.
    Merisko-Liversidge E; Liversidge GG
    Adv Drug Deliv Rev; 2011 May; 63(6):427-40. PubMed ID: 21223990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implementation of Quality by Design in the Formulation and Development of Nanocarrier-Based Drug Delivery Systems.
    Mehrotra S; Salwa A; Kumar L
    Crit Rev Ther Drug Carrier Syst; 2023; 40(3):1-46. PubMed ID: 36749082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quality by Design (QbD) and Design of Experiments (DOE) as a Strategy for Tuning Lipid Nanoparticle Formulations for RNA Delivery.
    Gurba-Bryśkiewicz L; Maruszak W; Smuga DA; Dubiel K; Wieczorek M
    Biomedicines; 2023 Oct; 11(10):. PubMed ID: 37893125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overview of drug product development.
    Narayan P
    Curr Protoc Pharmacol; 2011 Dec; Chapter 7():Unit 7.3.1-29. PubMed ID: 22147349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A review of emerging technologies enabling improved solid oral dosage form manufacturing and processing.
    Sohail Arshad M; Zafar S; Yousef B; Alyassin Y; Ali R; AlAsiri A; Chang MW; Ahmad Z; Ali Elkordy A; Faheem A; Pitt K
    Adv Drug Deliv Rev; 2021 Nov; 178():113840. PubMed ID: 34147533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of solid nanoparticle technology in the parenteral delivery of poorly water-soluble drugs.
    Kipp JE
    Int J Pharm; 2004 Oct; 284(1-2):109-22. PubMed ID: 15454302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quality-by-Design Concepts to Improve Nanotechnology-Based Drug Development.
    Rawal M; Singh A; Amiji MM
    Pharm Res; 2019 Sep; 36(11):153. PubMed ID: 31482243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lyophilized liposome-based parenteral drug development: Reviewing complex product design strategies and current regulatory environments.
    Wang Y; Grainger DW
    Adv Drug Deliv Rev; 2019; 151-152():56-71. PubMed ID: 30898571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.